Ardelyx ARDX Product sales, net — Concentration risk (as percent)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.
The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ardelyx's product sales, net — concentration risk (as percent).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ardelyx's product sales, net — concentration risk (as percent)?
- Ardelyx (ARDX) reported product sales, net — concentration risk (as percent) of 98.8% in Q1 2026.
- How has Ardelyx's product sales, net — concentration risk (as percent) changed year-over-year?
- Ardelyx's product sales, net — concentration risk (as percent) increased by 8.0% year-over-year, from 91.5% to 98.8%.
- What does product sales, net — concentration risk (as percent) mean?
- This metric measures the degree to which total product revenue is dependent on a limited number of customers, distributors, or specific therapeutic indications. A high concentration indicates significant exposure to the purchasing behavior or regulatory status of a small group of entities. Monitoring this helps investors evaluate the stability of revenue streams and the potential impact of losing key commercial relationships.